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EFFECTS OF PRENATAL GESTATIONAL DIABETES NUTRITION
EDUCATION CLASS AND INDIVIDUAL FOLLOW-UP ON MATERNAL AND
INFANT OUTCOMES
Samantha List, RD, LMNT
The University of Nebraska Medical Center, 2016
ABSTRACT
BACKGROUND: Gestational Diabetes Mellitus (GDM) is defined by glucose
intolerance detected with the onset of pregnancy, and if gone undetected and untreated,
can lead to morbidities for the mother and baby. Implementation of nutrition counseling
can work to reduce the risk of complications through dietary modification promoted and
adopted during pregnancy. Follow-up is important, as individual assessment is used to
modify recommendations. GDM class and follow-up provided through the Diabetes
Center of Nebraska Medicine covers and promotes proper management of blood glucose
(BG) during pregnancy for women with GDM.
PURPOSE: The purpose of this study was to assess the impact of GDM class and
follow-up with a Certified Diabetes Educator (CDE) on maternal and infant outcomes in
women diagnosed with gestational diabetes as well as to establish rate of individual
follow-up after GDM class attendance.
METHODS: A retrospective medical record review was conducted on women with
GDM who attended GDM class between the dates of July 2014-January 2015. The
primary maternal outcome was pregnancy weight gain and primary infant outcome was
lowest blood glucose. Secondary outcomes include mode of delivery, birth weight,
weight appropriateness for age, incidence of shoulder dystocia, involvement of NICU
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staff, and need for IV, heart, and respiratory support. An analysis of proportions and
means, via Fischer’s Exact Test and Mann-Whitney U Test, was preformed, as
appropriate, on variables between groups: mothers who attended class and follow-up
verse those who only attended class. Rate of follow-up with a CDE post GDM class was
also calculated.
RESULTS: Follow-up rate with a CDE after group class was 67.3%, leaving 32.7%
without follow-up, which may be linked to increased gravidity of those in the non-followup group (1.3 vs. 2.81, p=0.004). No significant differences in maternal and fetal
outcomes were identified between groups.
CONCLUSION: Findings indicate that group GDM class held at Nebraska Medicine’s
Diabetes Center, on its own, successfully communicates information to women with
GDM to aid in BG management and favorable outcomes.
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INTRODUCTION
Diabetes Mellitus (DM) is a group of metabolic diseases characterized by defects
in insulin secretion, action, or both resulting in hyperglycemia. One of these diseases,
Gestational Diabetes Mellitus (GDM), is defined by glucose intolerance detected with the
onset of pregnancy1. If gone undetected and untreated, GDM can lead to significant
morbidities for the mother and baby, during pregnancy and for the long term2.
Consequences include higher rates of stillbirth, polyhydramios, gestational hypertension,
macrosomia (birth weight >4000 grams), and caesarean delivery3; however, GDM risk
factors can be reduced with healthy dietary patterns promoted and adopted during
pregnancy through the implementation of nutrition counseling4.
Medical Nutrition Therapy (MNT) is the initial treatment for gestational diabetes,
generally characterized by a division of calories and carbohydrate over three meals and
two to four snacks, however, the diet is individualized to the person throughout followup5. Goals of MNT in gestational diabetes include achievement and maintenance of
normoglycemia, prevention of ketosis, and promotion of appropriate weight gain based
on maternal pre-pregnancy BMI6 as well as fetal wellbeing through adequate nutrition7,
as appropriate pregnancy weight gain has been associated with improved outcomes8.
Close follow-up is necessary to ensure nutritional adequacy, since individual
assessment of diet, weight changes, and blood glucose monitoring data is used to modify
nutrition recommendations. In fact, it is recommended that those with GDM visit a
registered dietitian (RD) a minimum of three times9, as nutrition counseling in this
population has resulted in reduced saturated fat and caloric intake10, decreased pregnancy
weight gain in obese women11, as well as decreased maternal fasting serum glucose
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levels12. Despite the benefits of and recommendations for nutritional counseling,
however, it has been shown that nutrition counseling rarely takes place at the
recommended frequency stated above13.
Gestational Diabetes class and follow-up provided through the Diabetes Center of
Nebraska Medicine is meant to cover and promote proper management of blood glucose
during pregnancy in mothers with gestational diabetes. Classes are led by registered
dietitians who are also certified diabetes educators (CDE), and follow-up appointments
are administered by either an RD, nurse, or exercise physiologist, who are all certified in
diabetes education. Education includes an overview of gestational diabetes, blood glucose
monitoring and goals, nutritional intervention and guidance, benefits and impact of
exercise, medication management, as applicable, and problem solving. Women who
attend individual follow-up are then provided with feedback based on blood glucose and
diet records upon which adjustments are made. In addition, these women are given more
information on breastfeeding and diabetes screening recommendations post-delivery. The
results of this study established the previously unknown rate of gestational follow-up
education at the Nebraska Medicine Diabetes Center, and will be used to evaluate the
existing gestational diabetes education program as well as directly influence program
alterations to improve overall patient care.
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Review of Literature
GDM – Definition, Diagnostic Criteria, and Prevalence
Gestational Diabetes Mellitus (GDM), is defined as glucose intolerance detected
with the onset of pregnancy1. Historically, the diagnosis of GDM across countries, based
on prevention of future onset DM in mothers, was highly variable, causing problems in
international discussion. Due to this, the International Association of Diabetes and
Pregnancy Study Groups (IADPSG) announced uniform diagnostic criteria to be used
worldwide1 based on the Hyperglycemia and Adverse Pregnancy Outcome (HAPO)
study15, conducted in 25,505 women in nine different countries to evaluate maternal and
fetal outcomes.
The HAPO study found that with increasing blood glucose (BG) levels following
the 75-gram oral glucose tolerance test (OGTT) between 24-32 weeks of gestation,
frequency of birth weight >90th percentile, caesarian section, and neonatal hypoglycemia
increased15. When comparing the highest 1-hour plasma glucose category to the lowest,
infants were more likely to be born at weights greater than the 90th percentile, (OR 4.49,
95% CI 3.16-6.39), women were more likely to have caesarian deliveries, (OR 1.86, 95%
CI 1.35-2.57) and infants were at more likely to experience hypoglycemia (OR 1.29, 95%
CI 0.51-3.31). Results from this study revealed that with elevated blood glucose exposure
to the fetus during pregnancy, the odds of maternal and fetal outcomes, described above,
also increased. Since no clear blood glucose level demonstrated an increase in primary
outcomes15, in 2008-2009, the IADPSG revised GDM diagnostic criteria and recommend
that all women without known diabetes undergo a 75-gram OGTT between 24-28 weeks
of gestation. Fasting, 1-hour, and 2-hour plasma glucose levels with an odds ratio 1.75
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times higher than the lowest category for fasting, 1-hour, and 2-hour plasma blood
glucose levels, was established for diagnosis. Please see Table 1 below for gestational
diabetes diagnostic criteria1.
Table 1. Screening and Diagnostic Criteria for Gestational Diabetes Mellitus1
Time Frame
Diagnostic Criteria
Fasting Plasma Glucose

>92 mg/dL

1-Hour Plasma Glucose

>180 mg/dL

2-Hour Plasma Glucose

>153 mg/dL

Patients are recommended to fast for a minimum of 8 hours prior to 75-gram OGTT,
which is to be administered between 24-28 weeks of gestation. To be diagnosed with
GDM, only one of the three above values must be exceeded1.
In a recent study involving 2,448 Italian pregnant women, the new IADPSG
diagnostic criteria (Table 1) were utilized in place of previous screening protocol. As a
result, 538 more women were screened, 31.8% of which were diagnosed with GDM. This
new diagnostic criteria required more GDM screening; however, it also identified 171
women with GDM who would have never been screened if previous protocol was left in
place21.
Although the ADA has now adopted this new criterion, the Committee on
Obstetric Practice continues to recommend a two-step approach to screening and
diagnosis. This process is different, as they recommend pregnant women to first be
screened with a 50-gram, 1-hour OGTT at 24-28 weeks of gestation and if failed, are
diagnosed based on the result of a 100-gram, 3-hour OGTT17. Although universal
diagnostic criterion is available, protocols continue to remain variable at this time.
According to the ADA (2013), about 7% of pregnancies are complicated by
gestational diabetes, ranging from 1 to 14% depending on diagnostic criteria used and

13
population studied. Based on these estimations, this amounts to approximately 200,000
cases of gestational diabetes each year1. DeSisto et al. (2014) aimed to provide current
data on the prevalence of GDM based on birth certificates and the Pregnancy Risk
Assessment Monitoring System and found that in 2010, prevalence of GDM was as high
as 9.2% in the United States. This study included records from 23,479 women in 15 states
and New York City. Additionally, this study group found that prevalence increased with
maternal age, number of children, and use of WIC, and decreased with higher education
(p<0.05)16.
Pathophysiology of GDM
During the first trimester of pregnancy, insulin sensitivity tends to be normal and
in some cases, greater than normal18. As pregnancy proceeds, however, insulin resistance
becomes more pronounced19, and according to Buchanan and colleges (1990), insulin
sensitivity can be reduced up to 60-80%20. Although this phenomenon is multifactorial, it
can be explained, in part, by increased secretion of progesterone, which decreases
glucose transport and insulin binding, and hormone placental lactogen, known to reduce
insulin sensitivity21. Additionally, plasma concentration of cortisol doubles during
pregnancy, which can induce insulin resistance when in excess22. In order to meet
elevated energy needs, endogenous glucose production (EGP) increases by 16-30%18. As
a result of impaired insulin sensitivity, glucose utilization, and EGP suppression, plasma
glucose levels after meals are higher and last longer in pregnancy. Though these changes
and mechanisms do occur in normal pregnancies, in cases of gestational diabetes, the
degree of insulin resistance is much more severe23.
As a compensatory response, in both normal pregnancies and those complicated
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by GDM, insulin secretion increases starting in the first trimester and is maximized by
the third24. To accommodate, the β-cells of the pancreas undergo both functional and
structural changes25 such as growth, proliferation26, and increased insulin secretion27.
When these actions are insufficient, abnormal glucose tolerance is observed. In fact,
Xiang and colleges (1999) estimate a 67% reduction in β-cell compensation in women
with GDM when compared to those with normal pregnancies28.
Risk Factors and Complications of GDM
In a study conducted by Griffin et al. (2000), subjects diagnosed with GDM were
significantly older (31 vs. 27 years, p<0.05) and weighed more (80 vs. 73.8 kg, p<0.05)
than those not diagnosed although parity was not significantly different29. In addition to
weight and age, the American Diabetes Association identifies high blood glucose,
abnormal cholesterol, smoking, inactivity, high blood pressure, and poor diet quality as
risk factors30. The CDC also includes family history of diabetes, having a multiple
pregnancy, and having GDM in a previous pregnancy as potential causes31. In a study
encompassing over 65,000 pregnancies, those with gestational diabetes in one pregnancy
had a 41% risk of developing GDM in a second, compared to a 4% risk in those who did
not have GDM previously14.
GDM has been linked to several adverse maternal and fetal outcomes. As
described earlier, the HAPO study found that women with GDM are at higher risk of
caesarian section, and their infants are born at birth weights >90th percentile and
experience neonatal hypoglycemia in greater frequency15. Langer and Mazze (1988) also
found a relationship between GDM and infant birth weight, demonstrating that as mean
BG levels and instability of glycemic control increased, incidence of large for gestational
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age (LGA) and macrosomatic infants also increased32. Another study focusing on
pregnant women less than 35 years of age with no previous GDM risk factors, rate of
caesarian section was significantly more common in women with gestational diabetes
when compared to those without (OR 2.36, 95% CI 1.53-3.64, p<0.001) and remained
significant after controlling for age, pre-pregnancy BMI, and parity (OR 1.92, 95% CI
1.21-3.06, p=0.006). Additionally, more newborns of GDM mothers were born large-forgestational-age (OR 3.53, 95% CI 1.34-9.34, p=0.011) and had significantly higher birth
weights (p<0.001) even after controlling for maternal age, pre-pregnancy BMI, and
gestational age at birth. Polyhydramnios, the excessive accumulation of amniotic fluid,
was also associated with GDM (OR 4.48, 95% CI 1.20-16.73, p=0.025) in addition to
admission to the NICU (OR 4.39, 95% CI 1.44-13.37, p=0.009)33.
GDM - Nutrition Therapy and Patient Outcomes
Medical Nutrition Therapy (MNT) is the initial treatment for gestational diabetes,
generally characterized by a division of calories and carbohydrate over three meals and
two to four snacks; however, specific recommendations should be tailored to the patient
throughout follow-up5,38. Goals of MNT in gestational diabetes include achievement and
maintenance of normoglycemia, prevention of ketosis, promotion of appropriate
pregnancy weight gain, based on maternal pre-pregnancy BMI6,35, and to support fetal
growth and wellbeing through adequate nutrition7. It is the position of the ADA that all
women with the diagnosis of GDM should receive nutritional counseling by a Registered
Dietitian when possible, and individualized MNT is recommended and should include
counseling on adequate calorie provision, appropriate macronutrient distribution, and
breastfeeding after delivery34. However, despite recommendations, a 2013 cross-sectional
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study found that 22% of women with gestational diabetes stated they never received
nutrition counseling from a registered dietitian and 65% visited an RD just once or twice
throughout their pregnancy13.
Supporting adequate weight gain during pregnancy has been shown to improve
infant and maternal outcomes. In a retrospective study involving 31,074 women during
the years of 2001-2004, appropriate weight gain throughout pregnancy, per Institute of
Medicine recommendations7, resulted in optimal outcomes while excessive weight gain
was associated with an increased odds of LGA infants (OR 1.72, 95% CI 1.53-1.93),
early delivery (OR 1.30, 95% CI 1.14-1.48), and cesarean delivery (OR 1.52, 95% CI
1.26-1.83). Additionally, those with suboptimal weight gain had greater odds of having
small-for-gestational age (SGA) infants (OR 1.39, 95% CI 1.01-1.90), but lower odds of
having LGA infants (OR 0.60, 95% CI 0.52-0.67)8. Please see Table 2 below for the
Institute of Medicine’s most recent weight gain recommendations based on prepregnancy Body Mass Index (BMI)35.
Table 2. Institute of Medicine Gestational Weight Gain Recommendations35
BMI Category
Pre-Pregnancy BMI
Total Weight Gain Recommendation
Underweight

<18.5 kg/m2

28-40 lbs

Normal Weight

18.5-24.9 kg/m2

25-35 lbs

Overweight

25-29.9 kg/m2

15-25 lbs

Obese

>30 kg/m2

11-20 lbs

Regulating calorie and macronutrient provision also aids in blood glucose
management. In women with GDM who had BMIs greater than 30 kg/m2, a 30-33%
calorie reduction (~1,600-1,800 calories per day) was effective in minimizing
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hyperglycemia and plasma triglycerides without inducing ketonuria, while diets with
50% reduction in calories (~1,200 calories per day) also minimized hyperglycemia, but
were associated with an increase in ketonuria36. Limiting carbohydrates to 35-40% of
total daily calories has been shown to reduce maternal BG and improve maternal and
infant outcomes. In a study conducted on women with diet-controlled GDM, a diet low in
carbohydrate, composed of less than 42% total calories from carbohydrate, was compared
to a high carbohydrate diet, with energy from carbohydrates exceeding 45% of total
calories. While the groups were demographically similar, postprandial BG levels were
significantly reduced in the low-carbohydrate group (p<0.04) and fewer participants in
this group required the addition of insulin therapy (p<0.047, RR 0.22; 95% CI 0.02, 1.00)
when compared to those consuming a high carbohydrate diet. In addition, incidence of
LGA infants was significantly lower in the low carbohydrate group when compared the
high-carbohydrate group (p< 0.035, RR 0.22, 95% CI 0.05, 0.91) and required fewer
caesarian sections (p< 0.037; RR 0.15; 95% CI 0.04, 0.94)37.
Physical Activity and Pharmacological Therapy for GDM
In addition to diet modification, regular aerobic exercise has also been shown to
lower fasting and post-meal BG and may be used in addition to nutritional therapy to
improve maternal BG control. Although the optimal frequency and intensity of exercise
for lowering maternal BG have not been established, it appears that at least three exercise
sessions weekly, greater than fifteen minutes each, are necessary to impact maternal BG
levels. In some cases, two to four weeks of regular exercise may be needed in order to see
an effect38,39.
When nutritional intervention alone is not enough to achieve normoglycemia,
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insulin therapy has been shown to reduce fetal complications most consistently34. If
insulin therapy is added to nutrition therapy, it is necessary to maintain consistent
carbohydrate distribution at meals and snacks to facilitate insulin adjustments39. Oral
glucose agents, such as glyburide, are not currently FDA approved for this population or
recommended as a method to lower BG in women with GDM; however, one non-blinded
clinical trial comparing glyburide to insulin therapy yielded similar perinatal outcomes40.
Although promising, more research needs to be conducted in this area to ensure its
safety34.
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METHODS
Participants
The institutional review board at the University of Nebraska Medical Center
(Omaha, NE) approved this study. This is a retrospective medical record review
conducted on mothers diagnosed with GDM who attended gestational diabetes class at
the Nebraska Medicine Diabetes Center from July 2014-January 2015 and their infants.
Classes are led by registered dietitians who are also certified diabetes educators (CDE),
and follow-up appointments are administered by a registered dietitian, nurse, or exercise
physiologist, who are all certified in diabetes education. Education includes an overview
of gestational diabetes, blood glucose monitoring and goals, nutritional intervention and
guidance, benefits and impact of exercise, problem solving, and medication management,
as applicable. Women who attend individual follow-up are then provided with feedback
based on blood glucose and diet records upon which adjustments are made. In addition,
these women are given more information on breastfeeding and diabetes screening
recommendations post-delivery.
This time period was chosen for the consistency of care provided, as there was
minimal staff turnover, and allowed enough time to pass for mothers who attended class
to reach delivery. GDM mothers less than 19 years of age, expecting a multiple
pregnancy, and those scheduled for group class but did not attend were excluded. After
extensive chart review, 49 mothers and 42 infants were eligible for this study. This
sample was then split further into follow-up (Group 1) and non-follow-up (Group 2)
groups, where those who attended GDM class and an individual follow-up appointment
were placed in Group 1, and those who only attended class were placed in Group 2.
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Data Collection
Clinical outcomes collected via retrospective chart review include: lowest infant
blood glucose, presence of infant hypoglycemia, infant birth weight, gestational age,
involvement of neonatal intensive care unit (NICU) staff, maternal pre-pregnancy BMI,
maternal weight gain, maternal weight gain according to recommended ranges, mode of
delivery (vaginal vs. caesarian section), average maternal blood glucose, and hemoglobin
A1c, as available. Other variables collected include: age, ethnicity, race, insurance, and
zip code, additional complications, serum calcium, method of feeding (formula vs.
breastfeeding), IV support, and APGAR score of the infants at birth. Presence of infant
hypoglycemia was defined by blood glucose less than 30 mg/dL and weight gain
recommendations were based on the Institute of Medicine parameters (see Table 2).
Health insurance was divided into two groups: public (Medicaid) and private (others).
Analysis
Women were separated into two groups: those who attended class in addition to
one or more follow-up appointments and those who attended GDM group class but did
not participate in a follow-up appointment. Those who were scheduled for group class but
did not attend were excluded. Rate of follow-up with a CDE post gestational diabetes
class was established by calculating proportion. Additionally, an analysis of proportions
and means, via Fischer’s Exact Test and Mann-Whitney U Test, was preformed, as
appropriate, on maternal and fetal outcomes between the two groups. Results with a pvalue <0.05 were deemed significant. In order to accept the two hypotheses, results must
demonstrate significantly improved fetal and maternal outcomes in the follow-up group
verse the group who attended group class with no follow-up.
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RESULTS
There were 33 mothers and 28 infants in Group 1, the follow-up group, and 16
mothers and 14 infants in Group 2, the group with no individual follow-up after group
class. There were no significant differences found in maternal baseline characteristics,
with the exception of gravidity, in which women in Group 2 had significantly more
previous pregnancies than women in Group 1. Results are displayed below in Table 1.
Table 3. Maternal Baseline Characteristics

Age (years)
Gravidity
Pre-Pregnancy BMI
(kg/m2)
Week of Gestation
1-Hour GTT
(mg/dL)
3-Hour GTT
(mg/dL)
HbA1c (%)
Ethnicity
Hispanic
Non-Hispanic
Race
White
Non-White
Health Insurance
Public
Private

Group 1

Group 2

Follow-Up

No Follow-Up

No.
33
30
33

Mean
28.36
1.3
31.23

SD
4.676
1.236
7.55

No.
16
16
15

Mean
29.19
2.81
37.12

SD
6.123
1.721
12.84

P-value
0.474
0.004*
0.161

32
28

27.25
184.86

6.825
25.2

16
11

30.88
168.45

3.704
34.9

0.123
0.318

24

127.54

31.12

7

121

31.9

0.620

8
No.
31
3
28
31
23
8
31
10
21

5.41
Proportion

0.75
%

5.12
Proportion

0.58
%

0.418
P-value
0.193

0.0968
0.9032

9.68
90.32

5
No.
15
4
11
15
11
4
16
9
7

0.2667
0.7333

26.67
73.33

0.7419
0.2581

74.19
25.81

0.3226
0.6774

32.26
67.74

* Significant p-value (p<0.05)
Gravidity = Number of previous pregnancies
GA = Gestational Age
BMI = Body Mass Index
GTT = Glucose Tolerance Test
HbA1c = Hemoglobin A1c

1.000
0.7333
0.2667

73.33
26.67

0.3750
0.4375

37.50
43.75

0.131
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From July 2014-January 2015 at the Nebraska Medicine Diabetes Center, 67.3%
of women who attended GDM group class also came back for follow-up, leaving 32.6%
of this sample without individual follow-up with a Certified Diabetes Educator after
group class (Figure 1).
Figure 1: Proportion of GDM Class Follow-Up vs. No Follow-Up
Follow-Up

No Follow-Up

32.7%

67.3%
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Results regarding maternal outcomes are displayed in Table 4, and visual displays
of maternal blood glucose levels and mode of delivery proportions, between groups, can
be viewed in Figures 2 and 3, respectively.
Table 4. Maternal Outcomes

Group 1

Group 2

Follow-Up
Average Maternal BG
(mg/dL)
Maternal Weight Gain
(lbs)
Weight Gain within
Recommended Range
Yes
No
Mode of Delivery
Vaginal
C-Section

No Follow-Up

No.
32

Mean
102

SD
10.5

No.
9

Mean
100

SD
10.2

P-value
0.670

26

20.2

17

12

21.5

16.7

0.888

No.

Proportion

%

Proportion

%

P-value
0.453

0.6923
0.3077

69.23
30.77

0.1667
0.8333

16.67
83.33

26
18
8
27
17
10

0.6296
0.3703

62.96
37.03

12
2
10
14
12
2

0.165
0.8571
0.1429

85.71
14.29

Recommended Weight Gain Based on Institute of Medicine Recommendations35
No statistical significance was found in average maternal blood glucose between
groups (p=0.670) and mean maternal weight gain was similar between groups, at 20.2 lbs
for those with follow-up and 21.5 lbs for those without follow-up (p=0.888). Although
not statistically significant, 69.23% of women in Group 1 (Follow-Up) experienced
weight gain within the recommended range per pre-pregnancy BMI, while only 16.67%
of women in Group 2 (No Follow-Up) gained weight within recommended ranges
(p=0.453). No significant difference was found in mode of delivery between groups (p =
0.165); however, it is worth noting that nearly 40% of those in the follow-up group
underwent caesarian sections compared to just 14.3% of women in Group 2.
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Figure 2. Average Maternal Blood Glucose between Groups

Figure 3. Mode of Delivery between Groups
Follow-Up

No Follow-Up

Vaginal

C-Section

17

10

Vaginal

C-Section

12

2
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Infant outcome results are exhibited in Table 5. In addition, a box plot of lowest
infant blood glucose levels and a bar graph demonstrating presence of hypoglycemia (BG
<30 mg/dL), between groups, can be viewed in Figures 4 and 5.

Table 5. Infant Outcomes

Gestational Age (weeks)
Birth Weight (grams)
Lowest BG (mg/dL)
APGAR Score (60 second)
APGAR Score (10 minute)
Presence of Hypoglycemia
Yes
No
Weight Appropriate for Age
Yes
No
Shoulder Dystocia
Yes
No
NICU Staff Present
Yes
No
Intravenous Support
Yes
No
Respiratory Support
Yes
No
Heart Support
Yes
No

No.
27
27
26
27
27
No.
26
5
21
27
24
3
26
1
25
26
14
12
26
8
18
26
4
22
26
0
26

Group 1

Group 2

Follow-Up

No Follow-Up

Mean
38.8
3523
42.8
7.3
8.3
Proportion
0.1923
0.8077
0.8889
0.1111
0.040
0.9615
0.5385
0.4615
0.3077
0.6923
0.1538
0.8462
0.000
1.000

Hypoglycemia defined as BG <30 mg/dL

SD No.
1.4
14
471.1 14
14.5 12
2.2
12
1.9
12
%
No.
12
19.23 1
80.77 11
14
88.89 14
11.11 0
12
4.00
0
96.15 12
13
53.85 8
46.15 5
12
30.77 4
69.23 8
12
15.38 2
84.62 10
12
0.000 0
100.0 12

Mean
38.6
3315
49.4
8.1
8.8
Proportion

SD
1.3
277.5
17.1
1.2
0.8
%

0.0833
0.9167

8.33
91.67

1.000
0.000

100.0
00.00

0.000
1.000

00.00
100.0

0.5333
0.4167

53.33
41.67

0.3333
0.6667

33.33
66.67

0.2000
0.8333

20.00
83.33

0.000
1.000

00.00
100.0

P-value
0.349
0.187
0.131
0.208
0.723
P-value
0.643

0.539

1.000

0.740

1.000

1.000

1.000
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Mean gestational age (GA) was similar between groups, at 38.8 weeks for those
in Group 1 and 38.6 weeks for infants in Group 2 (p=0.349). Mean birth weight between
groups was also similar, with averages of 3,523 grams for infants in Group 1 and 3,315
grams for infants in Group 2 (p=0.187). Although not statistically significant, 100% of
infants in Group 2 had birth weights appropriate for their age, while this was only true for
88.9% of infants in Group 1 (p=0.539).
When looking at average lowest blood glucose (Figure 4), differences were not
significant between groups (p=0.131), but there were 4 occurrences of infant
hypoglycemia (BG <30 mg/dL) in Group 1 (15.4%) and 1 incidence (8.3%) in Group 2.
Need for intravenous, respiratory, and heart support was similar between groups (p=1.00)
and aid of NICU staff was indicated in ~53% of births in both groups (p=0.740).
Figure 4. Lowest Infant Blood Glucose between Groups
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Figure 5. Presence of Infant Hypoglycemia between Groups
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DISCUSSION
Follow-Up Rate
More women who attended group class also attended an individual follow-up
appointment with a Certified Diabetes Educator than those who did not return for followup, 67.3% verse 32.7%, respectively. Reason for lack of follow up is unknown and likely
multifactorial; however, gravidity was significantly different between groups, with Group
1 having an average of one previous pregnancy and those in Group 2 having an average
of nearly three previous pregnancies (p=0.004). With this in mind, it may have been more
difficult for women in Group 2 to schedule and attend an additional appointment, as they
likely have more children to care for. Perception of risk may have also been
compromised in this group resulting in less motivation to attend individual follow-up,
since they have experienced a greater number of pregnancies in the past. Additionally,
these women could have had GDM in past pregnancies and may have already received
education in this area before. This could have contributed to higher confidence levels in
blood glucose management during pregnancy and, thus, less motivation to return for
follow-up.
Additional explanations for lack of follow-up may include late diagnosis of GDM,
delivery prior to scheduled follow-up appointment, overall perception that their case of
GDM is mild or low-risk, and lack of interest or desire to attend a follow-up appointment.
Maternal Outcomes
Mean maternal weight gain was similar between groups (p=0.888); however,
69.23% of women in Group 1 (Follow-Up) gained weight within recommended ranges
per pre-pregnancy BMI, compared to just 16.67% of women in Group 2, those with no
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individual follow-up (p=0.453). Although not statistically significant, this could suggest
that individual follow-up with a Certified Diabetes Educator after group GDM class may
aid expecting mothers in the management of weight gain throughout pregnancy.
Mode of delivery between groups was not statistically significant (p=0.165);
however, it is worth noting that nearly 40% of those in the follow-up group underwent
caesarian sections compared to just 14.3% of women in Group 2. Reason for this is
unknown; however, previous caesarian deliveries or increased severity of disease in the
women who returned to individual follow-up may be influencing these results.
The American Diabetes Association recommends that women aim for blood
glucose levels less than 140 mg/dL one hour after a meal and less than 120 mg/dL two
hours after a meal1. In this sample, no statistical significance was found in average
maternal blood glucose between groups (p=0.670), as mean BG levels were 102 and 100
for Group 1 and 2, respectively. Based on these results, it could be said that group
gestational diabetes class alone helped this sample of women stay within recommended
BG ranges; however, this information is limited to how well the patients monitored their
blood glucose levels in between appointments. Additionally, for apparent ethical reasons,
this study was designed without a true control group, as all women in this study received
gestational diabetes education. It would be interesting to compare these outcomes to
those of women with no specific gestational diabetes education at all.
Infant Outcomes
While mean gestational age (GA) and birth weight were similar between groups
(p=0.349 and p=0.187, respectively), infants in Group 1 had two instances of
macrosomia, defined as birth weight >4000 grams. When comparing percentage of
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infants born at weights appropriate for GA, 100% of infants in Group 2 were born at
appropriate weights compared to 88.9% of infants in Group 1; this finding, however, was
not statistically significant (p=0.539).
Between groups, no significant differences were found in average lowest blood
glucose (p=0.131). Group 1 did have more instances of infant hypoglycemia, at 15.4%
compared to 8.3% in Group 2, though not statistically significant (p=0.643). Need for
intravenous, respiratory, and heart support was similar between groups (p=1.00) and aid
of NICU staff was indicated in about 53% of births in both groups (p=0.740).
Reasons behind these findings are unclear, but one could postulate that women
who return for individual follow-up may be followed more closely by their physician due
to higher risk, and therefore, are more likely to return to follow-up with their CDE.
Number of previous pregnancies could also influence these results. As discussed earlier,
gravidity of women in Group 2 is significantly higher than the average gravidity of Group
1. Women who did not attend follow-up may have had GDM and education in previous
pregnancies, making them more proficient in the management of their BG levels
throughout pregnancy.
Limitations
Limitations of this study include its retrospective design, relatively small sample
sizes, and lack of a true control group. The data obtained for this study was limited to
what was documented in the electronic medical record and sample size was determined
based on the number of women who attended group GDM class during the predetermined, specified time period of this study (July 2014-January 2015). Since it is not
ethical to withhold available information and treatment from patients, all women in this

31
study received at least some gestational diabetes education, meaning this study had no
true control group for comparison.
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CONCLUSION
In conclusion, individual follow-up rate after group gestational diabetes class was
67.3%, leaving 32.7% without follow-up with a Certified Diabetes Educator at Nebraska
Medicine’s Diabetes Center. Lack of follow-up is likely related to number of previous
pregnancies, as gravidity in the follow-up group was significantly lower when compared
to the group without individual follow-up.
No significant differences in maternal and fetal outcomes were identified between
groups, perhaps related to limited sample size. Overall, findings from this study indicate
that group GDM class held at Nebraska Medicine’s Diabetes Center, on its own,
successfully communicates information to expecting mothers with gestational diabetes to
aid in blood glucose management and favorable maternal and infant outcomes.
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